07
Apr
As the global pharmaceutical landscape undergoes a seismic shift toward GLP-1 "miracle" drugs, Biocon is doubling down on a different mission: becoming the world’s primary provider of insulin. Kiran Mazumdar-Shaw, Chairperson of Biocon, recently outlined a strategic roadmap that positions the Indian firm to capture the market share being vacated by global giants like Novo Nordisk, Eli Lilly, and Sanofi. The strategy stems from a visible "recalibration" by major players. As these companies prioritize high-margin GLP-1 and incretin-based therapies, they are increasingly shifting away from complex insulin delivery systems like cartridges and pens. While GLP-1 drugs have revolutionized Type-2 diabetes…
